The PI3K/Akt pathway is involved in cardiac remodeling, especially hypertrophic cardiomyopathy, via the mTOR pathway, and empagliflozin can suppress the cardiac hypertrophy caused by the PI3K/Akt/mTOR pathway (134). The gene discussed is MTOR; the disease is cardiac hypertrophy.